Last reviewed · How we verify
NCT07308990
Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advanced Prostate Cancer
NA trial testing Radical prostatectomy with extended / limited lymph node dissection in Prostate Cancer Patients Undergoing Radical Prostatectomy in 800 participants. Currently enrolling.
30 May 2030
Quick facts
| Lead sponsor | N.N. Alexandrov National Cancer Centre |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 800 |
| Start date | 29 October 2025 |
| Primary completion | 30 May 2030 |
| Estimated completion | 30 May 2032 |
| Sites | 1 location across Belarus |
Drugs / interventions tested
- Radical prostatectomy with extended / limited lymph node dissection
- Radical prostatectomy with limited / no lymph node dissection
Conditions studied
- Prostate Cancer Patients Undergoing Radical Prostatectomy — all drugs for Prostate Cancer Patients Undergoing Radical Prostatectomy →
Sponsor
N.N. Alexandrov National Cancer Centre
Who can join
18 and older, male only, with Prostate Cancer Patients Undergoing Radical Prostatectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized controlled study assessing outcome of low (no or limited) versus high (limited or extended) extent of lymph node dissection in addition to radical prostatectomy in patients with operable localized or locally advanced prostate cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07308990
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer Patients Undergoing Radical Prostatectomy
Currently open trials in the same condition.
- NCT06636682 — FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer · Phase 2 · recruiting
Other N.N. Alexandrov National Cancer Centre trials
Trials by the same sponsor.
- NCT07472153 — PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemother · Phase 2, PHASE3 · recruiting
- NCT07472140 — PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficie · Phase 2, PHASE3 · recruiting
- NCT07524816 — Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07308990 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by N.N. Alexandrov National Cancer Centre
- Last refreshed: 30 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07308990.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing